Aquestive Therapeutics Plunges 7.96% on Q1 Earnings Miss

Aquestive Therapeutics' stock experienced a significant drop of 7.96% in pre-market trading on May 13, 2025, reflecting investor concerns and market sentiment.

Aquestive Therapeutics has made substantial progress in its drug development pipeline, particularly with Anaphylm, an oral sublingual film for severe allergic reactions. The company submitted a New Drug Application (NDA) for Anaphylm, which, if approved, could launch in the first quarter of 2026. This development is crucial as it represents a potential breakthrough in anaphylaxis management, offering a non-invasive treatment option.

The company's first-quarter 2025 financial results showed a decline in revenue and an increased net loss, which may have contributed to the stock's decline. Aquestive reported total revenues of $8.7 million, a 28% decrease from the same period in 2024, and a net loss of $22.9 million. The company has revised its 2025 guidance, expecting total revenue of $44-50 million and an adjusted EBITDA loss of $47-51 million. Despite these financial challenges, Aquestive's cash position remains robust at $68.7 million as of March 31, 2025.

In addition to its financial updates, Aquestive has been actively participating in various investor conferences, including the Citizens Life Sciences Conference and the Piper Sandler Spring Biopharma Symposium. These engagements provide the company with opportunities to present its advancements and engage with potential investors, which could influence market perception and future stock performance.